Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
According to GlobalData's high-prescriber survey, approximately 40% of LA HNSCC patients receive definitive chemoradiotherapy ...
Doctors say about 1 in 5 patients receiving immune checkpoint inhibitors develop acute kidney injury during treatment.
Multiple myeloma research led by researchers at the University of Calgary identified how tumor cells adapt after ...
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy Inhibiting the myeloid mimicry pathway along with ...
Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC). This is ...
4d
Targeted therapy to manage kidney complications may enable continuation of lifesaving immunotherapy
Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are ...
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results